Skip to search formSkip to main contentSkip to account menu

MK-8776

Known as: CHK1 Inhibitor MK-8776, Sch900776, Sch-900776 
An agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities. Chk1 inhibitor MK-8776… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent Terminology

Broader (2)

PyrazolesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL
Loss of function mutations of Enhancer of Zeste (Drosophila) homolog 2 (EZH2), the enzymatic component of Polycomb Repressive… 
2016
2016
Abstract 4835: Targeting the ATR/CHK1 axis in combination with PARP inhibition is more effective than PARP inhibition alone in BRCA mutant models
Introduction: Approximately 50% of high grade serous ovarian cancers (HGSOC) have defects in genes involved in homologous… 
2016
2016
Abstract B62: Evaluation of scheduling for triple therapy gemcitabine/CHEK1 inhibitor/WEE1 inhibitor in pancreatic cancer models
Sensitization of cancer cells to gemcitabine (Gem) has been shown with checkpoint kinase CHEK1 (CHK1) and WEE1 inhibitors. Our… 
2015
2015
Abstract 5316: Check point kinase 1 (Chk1) targeting as a novel therapeutic strategy in small cell lung cancer (SCLC)
Background: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer, accounting for 14% of lung cancers. It is… 
2015
2015
Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and molecular dynamics.
Chk1, a serine/threonine protein kinase that participates in transducing DNA damage signals, is an attractive target due to its… 
Highly Cited
2012
Highly Cited
2012
The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition
The Chk1 kinase is required for the arrest of cell cycle progression when DNA is damaged, and for stabilizing stalled replication… 
2012
2012
Abstract 1436: Therapeutic targeting of the DNA damage mediators CHK1 and Wee1 in neuroblastoma
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: High-risk neuroblastoma accounts for… 
2012
2012
Preclinical Development Preclinical Development of the Novel Chk 1 Inhibitor SCH 900776 in Combination with DNA-Damaging Agents and Antimetabolites
Many anticancer agents damage DNA and arrest cell-cycle progression primarily in S or G2 phase of the cell cycle. Previous… 
2011
2011
Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia
Abstract 1531 Checkpoint kinase (Chk1) is a serine-threonine kinase that is activated via phosphorylation in response to DNA… 
2010
2010
Abstract 2510: Efficacy of the Chk1 inhibitor SCH900776 at abrogating cell cycle arrest and enhancing DNA damage-induced cytotoxicity: Comparison with UCN-01
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Many anticancer agents damage DNA and arrest cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)